Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sobi will file for a re-examination of emapalumab in Europe following negative opinion by CHMP

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the Committee for Medicinal Products for Human use (CHMP) has adopted a negative opinion recommending a refusal of the marketing authorisation for emapalumab for the treatment of primary haemophagocytic lymphohistiocytosis (HLH) in children under 18 years of age in Europe. Given the significant unmet medical need that emapalumab addresses in patients with primary HLH with no approved treatments in Europe, Sobi will be requesting a re-examination by the CHMP with an expected opinion by end of year 2020. Primary HLH

Risk Intelligence successfully completes the DKK 8 million funding package

Risk Intelligence A/S (“Risk Intelligence” or the “Company”) announces today, that the Company has successfully completed the DKK 8 million funding package announced 9 July 2020.Risk Intelligence has finalised a long-term loan with Vækstfonden of DKK 4 million securing a funding package of DKK 8 million in total as communicated in the Press Release of 9 July 2020. Besides the DKK 4 million loan with Vækstfonden, the Company carried out a share capital increase earlier this month providing DKK 2 million and has a credit line with Danske Bank of DKK 2 million. This information is

Artificial Solutions: Invitation to presentation of Q2 report 2020

Artificial Solutions® (SSME:ASAI ), the leading specialist in enterprise-strength conversational AI, will release the interim report for the second quarter of 2020 on Thursday 30th July 2020 at 07:30 am (CET). The full report and a brief presentation will be available on: www.artificial-solutions.com/investor-relations.Conference Call - details Lawrence Flynn, CEO and Chris Bushnell, CFO will present the financial results at a telephone conference at 10:00 CET on the same day. In order to

Calmark recruits Jim Hansson for the role as Director of Production & Logistics

Calmark Sweden AB has hired Jim Hansson who will assume position as Director of Production & Logistics. Jim will be responsible for the development of Calmark's production and logistics, and will take office in October 2020.Jim Hansson has a wealth of experience from the field of medical devices. Over the recent years, he has worked as Production Manager and acting Site Manager at the Swedish listed company XVIVO Perfusion AB in Lund. He has previously held positions at Vivoline Medical AB, NOTE Lund AB, MAQUET Nordic AB and Jostra AB. Jim's experience includes continuous product

Financial Report April - June 2020

Financial Summary - Q2'20 · Underlying financial results better than expected, due to our Market Adjustment Initiatives (MAI) · Net Sales of $184 million declined 62% including an Organic Sales[1])  decline of 53% · Active Safety Net Sales of $79 million declined 57% including an Organic Sales decline of 56% · Operating Cash flow of $(107) million Outlook - FY'20 Indication  · Organic sales are expected to outperform the global LVP due to new program launches · Currency translation impact is expected to be (1)% · RD&E, net is expected to improve by more than $100

Flowscape gains ground in Sweden

One of Sweden's leading companies in the gaming industry chooses Flowscapes smart office solution for its office in Stockholm. The order value for the first year is 720,000 SEK and thereafter 190,000 SEK annually.“Another Swedish company has chosen Flowscape. Our future-proof smart office solution is once again proven to be the strongest on the market. The customer sees great value in using sensors both to enable Flowscapes innovative functions and to get the best possible data on how the office is actually used.”, says Anders Malmström, VP Sales & Marketing at Flowscape. The customer

Implementation of Capital Reduction in Dampskibsselskabet NORDEN A/S

ANNOUNCEMENT NO. 19 - 24 JULY 2020  At the annual general meeting on 12 June 2020 and the extraordinary general meeting on 23 June 2020 convened in Dampskibsselskabet NORDEN A/S, a proposal was adopted to reduce the Company’s share capital by DKK 1,500,000 from DKK 42,200,000 to DKK 40,700,000 by cancellation of treasury shares. The deadline for creditors to file their claims against the Company has now expired, without any claim being filed. The Board of Directors has therefore decided to implement the capital reduction, and the capital reduction has been registered with the Danish

Roman Ivashko appointed as SVP, Sales East division at Tikkurila

Tikkurila Oyj, Stock exchange release, 24 July 2020, at 11.00 a.m. (EEST) To further increase the efficiency and focus in leading sales, Tikkurila has decided to split the current sales function into two divisions: West and East. Divisions represent the company’s current external reporting segments. The current SVP Sales, Oskari Vidman, will take over the West division, corresponding to 66 percent of Tikkurila’s total revenue. Roman Ivashko has been appointed SVP, Sales, East division, as of September 1, 2020. He will also join the Tikkurila Management Team. Ivashko joins Tikkurila

Tikkurila Oyj’s Half year financial report for January−June 2020

Tikkurila Oyj’s Half year financial report for January−June 2020 Tikkurila OyjHalf year financial reportJuly 24, 2020 at 11:00 a.m. (EEST)  Tikkurila’s profitability clearly improved in Q2/2020 Original guidance for profitability restored, no guidance for revenue This is a summary of Tikkurila's Half year financial report. The full report is attached to this stock exchange release and is available on Tikkurila's website.  April−June 2020 highlights · Revenue increased by 1.3 percent to EUR 171.8 (169.7) million. Comparable revenue* increased by 4.6 percent. ·

RHEA Group and GomSpace Sign MOU

RHEA Group and satellite solutions provider GomSpace have recently signed a Memorandum of Understanding (MOU) to further combine their expertise on Security for Space and the development and operations of large constellations of SmallSats. The MOU consolidates a closer collaboration between the two companies as a result of past and ongoing activities in related fields. Under this MOU, the companies are partnering on security developments and monitoring operations associated with GomSpace’s present and future in-orbit satellite constellation activities, including taking advantage of RHEA’

Getinge to become CO₂ neutral by 2025

Today Getinge announces its intention to become a CO₂ neutral company by 2025. The target will be reached by a stepwise approach in several areas and supports the company’s objective to contribute to a sustainable health care environmentally as well as socially.To secure long-term value-creation and competitiveness, sustainability is an integral part of the organization, actively working to minimize the negative environmental footprint. Getinge is committed to achieving the Paris agreement goals of limiting global warming to 1.5 °C above pre-industrial levels, and has now made the decision

Zound appoints Jeremy de Maillard as new CEO

Zound Industries welcomes Jeremy de Maillard as new Chief Executive Officer. Jeremy brings international leadership experience and a proven track record of building brands and growing businesses at global and iconic brands such as adidas, The North Face and Vans. Jeremy is a strong and appreciated leader with a passion for connecting brands with consumers through an authentic brand purpose, innovative products and relevant consumer experiences in an ever changing, digitally driven and global market landscape.“Jeremy de Maillard is the perfect leader for Zound going forward. He brings strong

Letter from the CEO

As many of us head into a holiday break, I thought I would send out a short update, especially aimed at keeping our newer shareholders in the loop. On the whole things are progressing well, though we have several challenges due to the pandemic. US activity Nevisense 3.0 has been very well received by our US customers. We continue with two main focus areas in the US: our partnership with practice groups like Advanced Dermatology and Cosmetic Surgery (ADCS) and the reimbursement process. While the situation in New York is improving all the time, the high number of COVID-19 cases in

Swedencare AB (publ) HALF YEAR REPORT APRIL 1[ST]– JUNE 30[TH] 2020

A quarter characterized by a strong finish and acquisitionSUMMARY OF THE PERIOD SECOND QUARTER: APRIL 1ST – JUNE 30TH 2020 Numbers in parentheses refers to outcomes during the corresponding period of the previous year. - Net revenue amounted to 32 015 KSEK (30 376 KSEK), an increase of 5% - Organic, currency-adjusted growth amounted to 0% - Operating profit before depreciation (EBITDA) amounted to 7 424 KSEK (9 158 KSEK), corresponding to a decrease of 19% and an EBITDA-margin of 23,1% (30,1%) - Operating profit after depreciation (EBIT) amounted to 5 671 KSEK (8 657

Interim Report 1 January–30 June, 2020

The period April through June has been dominated by the negative impact of the corona pandemic on the entertainment and experience industry. During the quarter, net sales from operations amounted to SEK 14 million (168 million), which reflects the industry’s predicament under the powerful prevailing restrictions from the government. During the quarter, our focus was on managing the strained liquidity situation and creating a more flexible cost base to render operations more efficient in the future.A WORD FROM THE CEO Up until February, the year began strongly with an operating profit

Breztri Aerosphere approved in the US for COPD

24 July 2020 07:00 BST Breztri Aerosphere approved in the US for the maintenance treatment of COPD Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies AstraZeneca's Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The approval by the US Food and Drug Administration (FDA) was based on positive results from the Phase III ETHOS trial in

NCC and Salem Municipality to build Fågelsången school and sports hall

NCC has been commissioned by Salem Municipality to build Fågelsången school with capacity for 500 pupils as well as an adjacent sports hall. The project is a design-build contract with an order value of approximately SEK 320 million. Illustration: Sandellsandberg arkitekter “In the construction of Fågelsången school, we have paid close attention to location, landscape and nature. These will be beautiful, round buildings that will harmonize with the surrounding urban environment and the hilly landscape. About 500 pupils in Salem will soon have access to a wonderful place for

Hexagon Interim Report 1 January - 30 June 2020

Second quarter 2020 - Net sales decreased by -8 per cent to 896.6 MEUR (976.0). Using fixed exchange rates and a comparable group structure (organic growth), net sales decreased by -10 per cent - Operating earnings (EBIT1) decreased by -5 per cent to 226.5 MEUR (239.2) - Earnings before taxes, excluding non-recurring items, amounted to 220.1 MEUR (232.3) - Net earnings, excluding non-recurring items, amounted to 180.5 MEUR (190.5) - Earnings per share, excluding non-recurring items, amounted to 0.49 EUR (0.52) - Operating cash flow increased to 239.2 MEUR (178.3)

Electrolux Professional AB interim report Q2 2020

Second quarter, April-June 2020· The quarter was heavily impacted by the COVID-19 pandemic. Net sales amounted to SEK 1,489m (2,455). Sales decreased by 39.3%. Organically sales decreased by 39.9%. · EBITA amounted to SEK –4m (418), corresponding to a margin of –0.2% (17.0). · Operating income amounted to SEK –18m (401), corresponding to a margin of –1.2% (16.3). · Operating cash flow after investments amounted to SEK 31m (432). · Income for the period amounted to SEK –28m (126), and earnings per share was SEK –0.10 (0.44). · Net debt/EBITDA was 1.3x (0.1). · Actions were

Finnair Group Half-year Report 1 January – 30 June 2020

Finnair Plc        Half-year Report      24 July 2020 at 9.00 a.m. EEST COVID-19 grounded Finnair’s passenger operations to a near halt and revenue was mainly driven by cargo-only operations, cash position and equity were restored to pre-pandemic level April–June 2020 · Earnings per share were -0.25 euros (0.04). · Revenue decreased by 91.3% to 68.6 million euros (789.1)*. · Fuel costs decreased by 147.3 million euros (-81.6%) due to the COVID-19-related decline in capacity although it was partly netted by the impact of changes in fuel prices**. · The comparable

myFC Holding AB (publ) interim report January – June 2020

Quarter April – June 2020· Net sales amounted to SEK 0 (0) · Operating loss amounted to SEK -15 million (-107) · Earnings per share amounted to SEK -0.10 (-1.37) Significant events April – June · Michael Glantz appointed CEO of myFC · Sebastian Weber appointed CTO of myFC · myFC demonstrates hybrid concept for electric vehicles Significant events after the end of the period · Extraordinary general meeting resolves targeted new share issuesgenerating approximately 52 million SEK. Comment from CEO Michael Glantz: ”On June 17, we demonstrated a fully

Calliditas reorganizes its management team

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it has reorganized its management team.From today, the company’s management team will consist of: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Dr Richard Philipson, CMO Frank Bringstrup, Vice President Regulatory Affairs Andrew Udell, Head of North America, Commercial Katayoun Welin-Berger, Vice President Operations “Calliditas will continue to build and benefit from a broad and highly competent senior team which operates in an integrated manner.  As the company has grown there is now need for a

INTERIM REPORT, January-June 2020

Strong quarter with improved KPI’s Second quarter of 2020                                      · Consolidated net sales increased by 7 percent to SEK 949 m (889), of which organic growth amounted to 7 percent · Net sales in Product & Solutions amounted to SEK 753 m (688) and in Installation Services to SEK 228 m (234) · Gross profit increased to SEK 282 m (238), Gross margin increased to 29.8% (26.7%) · EBITDA increased to SEK 166 m (124), EBITDA margin increased to 17.4% (13.9%) · Operating profit (EBIT) increased to SEK 137 m (95), EBIT margin increased to 14.4% (10.7%)

There are no items matching the current filter
There are no more items matching the current filter
Back to top